Bioquell Pod featured at Infection Prevention 2014 Conference
The Infection Prevention 2014 Conference will feature a series of presentations by NHS hospital representatives that have been using the Bioquell Pod to improve their infection control practices. The Bioquell Pod is an infection control enclosure that has been designed to limit the spread of pathogens in ward environments and can be used to convert units into single occupancy rooms. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Patient care infection control isolation Latest News pathogen spread Source Type: news
MSD announces presentation of data on investigational use of pembrolizumab in gastric cancer
MSD, known as Merck in the United States and Canada, announced the first presentation of data on the investigational use of pembrolizumab – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced gastric cancer. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 30, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology anti-PD-1 therapy gastric cancer Latest News pembrolizumab Source Type: news
MSD announces presentation of data on investigational use of pembrolizumab in advanced bladder cancer
MSD, known as Merck in the United States and Canada, announced the first presentation of data on the investigational use of pembrolizumab – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). The early findings presented showed a confirmed overall response rate of 24 percent with pembrolizumab as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI, 10.3-43.5) including a complete response rate of 10 percent (3/29). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 30, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology bladder cancer Latest News pembrolizumab safety data Source Type: news
Promising combination treatment gives additional hope to patients with the most aggressive form of skin cancer
New data announced has demonstrated that combinational treatment of cobimetinib with Zelboraf® (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, (1,2) in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone. (3) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 29, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology advanced melanoma BRAFV600 mutation-positive cobimetinib Latest News vemurafenib Source Type: news
FDA approval for ILUVIEN® in DME strengthens Alimera Sciences in global ophthalmology arena
Alimera Sciences Inc., a pharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, today announced that the US Food and Drug Administration (FDA) has approved ILUVIEN® for the treatment of diabetic macular oedema (DME). This comes nearly 18 months after the treatment became available in the UK and Germany, having received an approvable response via the European Decentralised Procedure in February 2012. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 29, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes Ophthalmology diabetic macular oedema ILUVIEN intravitreal implant Latest News Source Type: news
Effect of statins on diabetes risk and bodyweight related to mechanism of action
The mechanism by which statins increase the risk of type 2 diabetes has been investigated in a large-scale analysis from an international team led by researchers from UCL and the University of Glasgow, using information from genetic studies and clinical trials. Published in The Lancet, the work received support from a number of funders including the Medical Research Council, British Heart Foundation, Rosetrees Trust and National Institute for Health Research University College London Hospitals Biomedical Research Centre. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 24, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Industry News Cardiovascular medicine Diabetes body weight genetic variance Latest News LDL cholesterol statins type 2 diabetes Source Type: news
New IDegLira data show glycaemic improvements in type 2 diabetes
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUALTM study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes blood glucose targets diabetes type 2 insulin degludec/liraglutide Latest News Source Type: news
VIBATIV® targets hospital acquired pneumonia from MRSA across Europe
Clinigen Group plc announced that the new first-in-class bactericidal, once-daily, injectable lipoglycopeptide antibiotic VIBATIV® (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia – HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Infectious Disease antibiotic HAP Latest News mrsa telavancin Source Type: news
Data from health economic model shows cost of managing hypoglycaemia
New figures released show the cost of managing hypoglycaemia in the UK could be £363.6 million per year (£235.6 million for severe episodes and £128 million for non-severe). The economic burden of hypoglycaemia, calculated using the Local Impact of Hypoglycaemia Tool (LIHT), was presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 17, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Cost effectiveness Industry News Diabetes EASD hypoglycaemia hypoglycaemic episodes Latest News LIHT Source Type: news
Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes (T2D) already taking metformin and in those who were previously untreated. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 16, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes empagliflozin/linagliptin Latest News metformin sustained efficacy type 2 diabetes Source Type: news
Improved HPV vaccine uptake could prevent 200 cervical cancer cases every year
Around 200 cases of cervical cancer and 90 deaths from the disease could be prevented each year if uptake of the HPV (human papillomavirus) vaccine was increased in every region to just ten per cent more than the current national average, according to research1 presented at the Public Health England conference in Warwick. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 16, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Drug delivery Industry News cervical cancer hpv vaccination Latest News uptake variation Source Type: news
Intarcia announces two presentations at 50th EASD meeting
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Industry News Diabetes GLP-1 therapy ITCA 650 Latest News subcutaneous osmotic pump type 2 diabetes Source Type: news
New technology may uncover the root of critical infections and cut health care costs
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Cost effectiveness Industry News Healthcare costs Latest News PCR/ESI-MS RADICAL study Source Type: news
Boehringer Ingelheim and Eli Lilly announce data on diabetes portfolio
Data to be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) Diabetes Alliance. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Diabetes clinical evidence Latest News safety profile T2D Source Type: news
TONADO™ study shows further benefits in COPD
Data from the pivotal Phase III TONADO™ studies for tiotropium + olodaterol Respimat® fixed dose combination (FDC) were presented for the first time at the European Respiratory Society (ERS) International Congress 2014 in Munich. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Industry News Respiratory copd fixed dose combination Latest News phase iii trial tiotropium olodaterol Source Type: news
